Carbamazepine Biosensor Development for Epilepsy Patient Screening.

  • publication
  • 12-12-2021

Pino EJ, Pucheu F, Alvarado F, Gomez B, De Diego M, Mennickent S, Aguayo C, Pena C, Rodriguez A. Annu Int Conf IEEE Eng Med Biol Soc 2021 Nov;2021():1531-1534. 10.1109/EMBC46164.2021.9629901.

The San Carlos population in Chile is an example of an underserved community due to lack of timely access to regular controls and laboratory results. One particular challenge is the adherence to treatment of Epilepsy patients. In this work, we present the design and proof-of-concept of a Point of Care Device (POCD) to measure carbamazepine levels in saliva to screen for correct dose prescription among epilepsy patients. We present the Screen Printed Electrode design and activating circuit and preliminary results to verify feasibility of the biosensor. Future steps include the fabrication of the device itself and validation with the target population.

see on Pubmed